| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Methods and compositions for mhc class ii invariant chain polypeptide use as a macrophage migration inhibitory factor receptor | JP2002577925 | 2002-03-29 | JP4202763B2 | 2008-12-24 | ドネリー，シェーマス; ブカラ，リチャード・ジェイ; ミッチェル，ロバート; メッツ，クリスティーン・エヌ; レン，リン |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 2 | Methods and compositions for mhc class ii invariant chain polypeptide use as a macrophage migration inhibitory factor receptor | JP2002577925 | 2002-03-29 | JP2004532839A | 2004-10-28 | ドネリー，シェーマス; ブカラ，リチャード・ジェイ; ミッチェル，ロバート; メッツ，クリスティーン・エヌ; レン，リン |
| マクロファージ遊走阻止因子（ＭＩＦ）に対するレセプターとしてＭＨＣクラスII不変鎖ポリペプチド、Ｉｉ（また、ＣＤ７４として知られる）を使用するための方法及び組成物が公開される。 これらには、局所的又は全身的に変化したＭＩＦレベルで特徴付けられる状態、特に炎症状態及びガンの治療におけるこのレセプター、並びにこのレセプターに結合する若しくはそれ以外にＣＤ７４とＭＩＦとの相互作用又はその相互作用の結果を変調させるＭＩＦのアゴニスト及びアンタゴニストを使用するための方法及び組成物を含む。 | ||||||
| 3 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | EP02725395.4 | 2002-03-29 | EP1383919A1 | 2004-01-28 | BUCALA, Richard, J.; DONNELLY, Seamas; LENG, Lin; METZ, Christine, N.; MITCHELL, Robert |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 4 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | US15339778 | 2016-10-31 | US20180105593A1 | 2018-04-19 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MEW class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 5 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | US12781546 | 2010-05-17 | US20110020321A1 | 2011-01-27 | Richard J. BUCALA; Lin LENG; Christine N. METZ |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 6 | Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor | US10108383 | 2002-03-29 | US20030013122A1 | 2003-01-16 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 7 | Method of inhibiting binding or activity of MIF by administering a MIF antagonist | US14090183 | 2013-11-26 | US09221903B2 | 2015-12-29 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 8 | Method of inhibiting binding or activity of MIF by administering a MIF antagonist | US12781546 | 2010-05-17 | US08617822B2 | 2013-12-31 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 9 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | US13160265 | 2011-06-14 | US20120039914A1 | 2012-02-16 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 10 | Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor | US11931442 | 2007-10-31 | US20080146507A1 | 2008-06-19 | Richard J Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 11 | Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor | US11231990 | 2005-09-22 | US20060024754A1 | 2006-02-02 | Richard Bucala; Lin Leng; Christine Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 12 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | EP02725395.4 | 2002-03-29 | EP1383919B1 | 2010-07-07 | BUCALA, Richard, J.; DONNELLY, Seamas; LENG, Lin; METZ, Christine, N.; MITCHELL, Robert |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 13 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDE AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | EP02725395 | 2002-03-29 | EP1383919A4 | 2004-12-01 | BUCALA RICHARD J; DONNELLY SEAMAS; LENG LIN; METZ CHRISTINE N; MITCHELL ROBERT |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 14 | METHOD OF INHIBITING BINDING OR ACTIVITY OF MIF BY ADMINISTERING A MIF ANTAGONIST | US14949484 | 2015-11-23 | US20160152708A1 | 2016-06-02 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 15 | METHODS AND COMPOSITIONS FOR USING MHC CLASS II INVARIANT CHAIN POLYPEPTIDES AS A RECEPTOR FOR MACROPHAGE MIGRATION INHIBITORY FACTOR | US14295692 | 2014-06-04 | US20150010570A1 | 2015-01-08 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 16 | MIF antagonists | US13160265 | 2011-06-14 | US08779099B2 | 2014-07-15 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 17 | METHOD OF INHIBITING BINDING OR ACTIVITY OF MIF BY ADMINISTERING A MIF ANTAGONIST | US14090183 | 2013-11-26 | US20140178403A1 | 2014-06-26 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 18 | Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor | US11931442 | 2007-10-31 | US07741057B2 | 2010-06-22 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 19 | Methods and Compositions for Using MHC Class II Invariant Chain Polypeptide as a Receptor for Macrophage Migration Inhibitory Factor | US12098220 | 2008-04-04 | US20090263404A1 | 2009-10-22 | Richard J. Bucala; Lin Leng; Christine N. Metz |
| Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer. | ||||||
| 20 | 광학 필름 교체식 고선명 윈도우를 구비한 평판형 암 진단 키트 | KR1020160067606 | 2016-05-31 | KR101666952B1 | 2016-10-28 | 신동진 |
| 본발명은광학필름교체식고선명윈도우를구비한평판형암 진단키트에관한것으로, 소변의티로신(L-Tyrosine)을유멜라닌으로전환시키는티로신반응에의해색상을변화시켜암 및대사질환의존재여부를진단할수 있도록하며, 변화된색상을왜곡없이선명하게관찰할수 있도록한 것이다. 이러한본 발명은, 투명윈도우를구비한평판형케이스와; 상기케이스의내부로삽입장착되어상기윈도우를통해육안으로관찰되도록하며상기투입구로투입되는소변과반응하는효소카트리지와; 상기케이스전면에결합되고상기윈도우에대응하는개구부를구비한필름틀과; 필름틀에교체가능하도록착탈식으로끼워져서윈도우전면에서외부광에의한색상왜곡을방지하는광학필름과; 효소카트리지에존재하며, 티로시나아제(Tyrosinase), 도파크롬상호변이효소(Dopachrome tautomerase, DCT) 및티로시나아제-관련단백질 1(Tyrp1)을포함하여, 소변내에존재하는티로신(L-Tyrosine)을멜라닌으로전환시키는티로신검출용효소조성물로이루어지며, 상기효소카트리지에존재하는티로신검출용효소조성물의티로신반응에의한색상변화를윈도우및 광학필름을통해피검수자의육안으로관찰할수 있도록한 것을특징으로한다. | ||||||
QQ群二维码
意见反馈
意见反馈